Regeneron Pharmaceuticals, Inc. (REGN) stock analysis

In our weekly check, Regeneron Pharmaceuticals, Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 2, red flags: 1.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as REGN.

What our checks show for REGN

Red flags

Warning signs

Strengths

Next earnings report: 2027-01-28

Similar companies

MRNA · VRTX · ARGX · ONC · RVMD · GMAB

Questions

What grade does Regeneron Pharmaceuticals, Inc. (REGN) have?

In our weekly check, Regeneron Pharmaceuticals, Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 22 pass, warnings: 2, red flags: 1. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of REGN stock?

This week's biggest flags for Regeneron Pharmaceuticals, Inc.: Margins falling, Deep past fall, Slow recovery after falls. In total 3 of 25 checks show a warning or a red flag.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as REGN.

When does Regeneron Pharmaceuticals, Inc. report earnings next?

The next earnings report is expected on 2027-01-28. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis